Villya Pharmaceuticals

Villya Pharmaceuticals is a private Florida-based pharmaceutical company focused on developing second-generation formulations of existing medicines using a proprietary water-solubility and drug-loading technology. The company appears to be pursuing improved versions of praziquantel-based therapies for female genital schistosomiasis and water-soluble erectile dysfunction therapeutics such as sildenafil-related formulations. Its approach is centered on improving bioavailability, reducing dose burden, enabling alternative routes of administration, and potentially improving onset and tolerability. Publicly available information indicates an early-stage company built around patents and formulation innovation rather than a late-stage clinical pipeline. The business also appears open to partnerships, licensing, and possible U.S.-based manufacturing.